Resources

Publications

05/28/2022
- Oncology
Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-world Pan-Cancer Cohort
BMC Cancer, Tempus-authored
05/26/2022
- Oncology
Circulating Tumor DNA (ctDNA) Mutations Associate With Response in Patients (Pts) With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated With Talazoparib (TALA) and Temozolomide (TMZ)
ASCO 2022
05/26/2022
- Oncology
Microsatellite-Stable Tumors With High Tumor Mutational Burden in Association With Tumor Response to Immune Checkpoint Inhibitor Therapy Across Solid Tumors and Correlation With Specific Oncogenic Alterations
ASCO 2022
05/26/2022
- Oncology
PTCH1 and AXIN2 Modulation of AR Copy Number Effects on AR Gene Overexpression in Metastatic Castration Resistant Prostate Cancer (mCRPC)
ASCO 2022
05/26/2022
- Oncology
Genetic Alterations in Tumor Tissue and Cell-Free DNA in Patients With Papillary Thyroid Carcinoma at Initial Surgery
ASCO 2022
05/26/2022
- Oncology
Long-term Survival in Newly-Diagnosed Ovarian Cancer Patients
ASCO 2022
05/26/2022
- Oncology
Real-world evidence on predictors of survival for hormone-positive and triple-negative advanced breast cancer by treatment and BRCA status in the United States
ASCO 2022
05/26/2022
- Oncology
Investigating the Impact of NGS Data Availability on Clinical Decision-Making in Brain Cancer
ASCO 2022
05/26/2022
- Oncology
CRESTONE: Initial Efficacy and Safety of Seribantumab in Solid Tumors Harboring NRG1 Fusions
ASCO 2022
05/26/2022
- Oncology
Targeting B7-H3 in Prostate Cancer: Phase 2 Trial in Localized Prostate Cancer Using the Anti-B7-H3 Antibody Enoblituzumab, With Biomarker Correlatives
ASCO 2022

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53